01
Where it responded fast
In hundreds of patients the developer observed GRBM acting as a very fast, very effective answer for many cancer cells.
02 / HOLOBIONT THEORY
Medicine borrowed nature's materials;
now we borrow nature's method
External miRNA — a tiny signaling substance made in the dialogue between plants and their beneficial bacteria. The key substance of future medicine found by the developer, and a starting point for next-generation cancer research.
In plain words
Plants and the beneficial bacteria inside them talk by exchanging very small signaling substances. What arises from that dialogue is External miRNA. I distinguished it from miRNA acting within cells of the same species (InCell miRNA) and named this cross-species substance External miRNA.
In my research it was highly compatible with human cells, and the same results were seen in hundreds of people. I believe External miRNA helps repair damaged DNA and cell membranes, lengthen telomeres, neutralize RNA viruses, and return cancer cells to normal cells.
And Plantaricin, a natural antimicrobial made by plant lactic acid bacteria (L. plantarum), blocks harmful microbes. Two substance groups, two defense mechanisms. The key question is who can mass-produce them, and how. Who: Vital Probiotics. How: the VPMI method.
130 years of progress — cut, burn, attack, target, awaken
| Stage | Began | Origin | How it works | Remaining challenge |
|---|---|---|---|---|
| Surgery | 1890s | Hand and scalpel | Removes the tumor | Metastasis, invisible cells |
| Radiation | 1896 | X-rays, radium | Destroys cells by damaging DNA | Damage to surrounding normal tissue |
| 1st-gen chemotherapy | 1942 | Poison gas, plants | Attacks rapidly dividing cells | Normal cells are harmed too |
| 2nd-gen targeted therapy | 1998 | Specific cancer molecules | Targets specific molecules only | Resistance; works only where targets exist |
| 3rd-gen immunotherapy | 2011 | The body's immunity | Releases the brakes on immunity | Only some patients respond; immune side effects |
Many of these advances started from nature. But all used nature's substances as weapons to destroy cancer cells. None started by studying how nature itself responds to cellular errors and mutations. I believe this is the shared limit of cancer treatment so far.
Where nature responds best to cellular errors:
the fetus
The embryonic environment has been reported to let even malignant cells grow into normal tissue. That power converges in a fetus interacting well with microbes.
Read moreCloseInCell vs. External miRNA, the solid layer, observations and limits
InCell miRNA and External miRNA
| Item | InCell miRNA | External miRNA |
|---|---|---|
| Role | Intracellular regulation, mainly within the same species | Cell-to-cell and cross-species communication |
| Structure | Tertiary structure | Simple, symmetric secondary structure |
| Persistence | Relatively short | Longer (developer's estimate: up to about 38 years) |
| Research view | Biomarker-centered (mainstream research) | The core substance of GRBM and of future medicine |
It does not appear in ordinary lactic acid bacteria, but through my own experiments I found that plant LAB inside young plants free of chemicals and salt produce and send External miRNA as a signaling substance to form a genetic relationship with their host. To industrialize this, I created the concept of Vital Probiotics, an evolution of ELAB, which produces genetic material far more powerfully and abundantly to form the metabolome.
The frontier is already turning toward microbes
In 2018, studies in Science showed one after another that the composition of gut microbes shapes the response to immunotherapy, and in 2021 some melanoma patients who had not responded to immunotherapy did respond after fecal microbiota transplantation. The frontier of cancer treatment is moving toward interaction with microbes. Meanwhile, turning synthetic miRNA into a drug proved difficult — an early clinical trial was halted because of immune-related side effects. That is why a process that mass-produces "nature-made External miRNA" is decisive.
What the developer witnessed, and what remains
02
Where it is still hard
Autologous cell mutations from aging, and cancer cells accumulated in large amounts of body fat, remain hard to address this way.
03
Next research
Isolating and purifying External miRNA and Plantaricin from the solid layer, for a next-generation approach applied directly to tumor sites.
I hope that investment and much more research will make this a starting point for conquering cancer in the next generation. GRBM does not replace standard cancer care, and these observations are to be confirmed by disease-specific clinical papers and independent verification.
Literature: miRNA transfer via exosomes (Nature Cell Biology, 2007), gut microbes and immunotherapy response (Science, 2018), fecal microbiota transplantation in melanoma (Science, 2021), GLOBOCAN 2022 (CA Cancer J Clin, 2024). Observations and interpretation: source — the developer's (Wooyoung Nam's) research.
PARTNERSHIP · INVESTMENT
The world's first true eco-bio platform technology —
we are looking for the one partner
After signing an NDA you can review the materials, then verify the original records and the process in person during on-site due diligence in Uljin, Gyeongsangbuk-do, Korea.